Infectious disease
The FDA indicated that, based on new evidence, there was not enough supporting evidence for the two drugs to be considered effective in treating COVID-19.
The U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020 – if it clears the clinic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
Eli Lilly will assess its JAK1/JAK2 inhibitor Olumiant (baricitinib) as a potential treatment for COVID-19 in a Phase III study.
Sinovac Biotech announced positive early data from a Phase I/II clinical trial of its COVID-19 vaccine, CoronaVac. The vaccine showed both favorable immunogenicity and safety.
Convalescent and Therapeutic Antibodies and Older Vaccines Suggest Glimmers of Hope Against COVID-19
The amount of scientific information unearthed about SARS-CoV-2, the virus that causes COVID-19, in only six months is unprecedented. The speed is remarkable, although much of it will still need to be confirmed over time with more careful study. Still, each day presents new data with a glimmer of hope. Here’s a look at some recent findings.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
The primary endpoint of the trial will be prevention of symptomatic COVID-19 disease, with key secondary endpoints including prevention of severe COVID-19, defined as hospitalization, and prevention of infection by SARS-CoV-2.
In an interview, Lilly’s CSO said the third antibody could possibly begin human trials in the new few weeks. But the statement that got everyone more excited was when he indicated one of the antibodies might be available for use by September.
PRESS RELEASES